Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Glioblastoma 45Neuroblastoma 16Glioma 16Brain Neoplasms 14Astrocytoma 10Neoplasms 8Rhabdomyosarcoma 7Sarcoma, Ewing 6Recurrence 5Oligodendroglioma 5Medulloblastoma 5Sarcoma 4Osteosarcoma 4Melanoma 4Small Cell Lung Carcinoma 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Lymphoma 3Gliosarcoma 3Diffuse Intrinsic Pontine Glioma 3Wilms Tumor 2Rhabdoid Tumor 2Pyloric Stenosis, Hypertrophic 2Ovarian Neoplasms 2Neoplasm Metastasis 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3Everolimus 3lutetium Lu 177 dotatate 2Temozolomide 2Sunitinib 2sargramostim 1montanide ISA 51 1lanreotide 1incomplete Freund's adjuvant 1fludarabine phosphate 1belzutifan 1Sorafenib 1Radiofrequency Ablation 1Octreotide 1Interleukin-13 1Histocompatibility Testing 1Gefitinib 1Fulvestrant 1Fluorodeoxyglucose F18 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1Colony-Stimulating Factors 1Capecitabine 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Adenoma, Islet Cell × Temozolomide × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

NCT05040360 2025-12-15

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

SWOG Cancer Research Network

Phase 2 Recruiting
141 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡